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Abstract
Australia supports the control of tuberculosis
in Papua New Guinea for reasons of aid effec-
tiveness and a desire to decrease the chance of
importing tuberculosis to Australia. This
paper analyses the case for this support using
both cost-utility and cost-benefit analysis. We
reach three conclusions. First, Australia
directly benefits from its investment in control-
ling tuberculosis in Papua New Guinea, with a
cost of $US 13 million (in 2012 prices) over 10
years earning a net present value of $US 22
million. Second, the longer and more extensive
the basic directly observed short course
therapy, or basic DOTS, to control tuberculo-
sis, the higher are the returns for Australia.
Finally, in addition to surpassing all com-
monly used benchmarks for being a cost-
effective investment for Australia, a basic
DOTS expansion also generates a health
benefit for Papua New Guinea that compares
well as one of the ‘ten best health buys’ in
developing countries.
Key words: tuberculosis, DOTS, Papua New
Guinea, aid
1. Introduction
Tuberculosis (TB) has been in existence for at
least 17,000 years (Rothschild et al. 2001). At
the point of greatest public concern, in the
nineteenth and early twentieth centuries, it
caused nearly 25 per cent of all deaths in
Europe (Bloom 1994). Mortality since has dra-
matically decreased, by nearly 90 per cent up
to the 1950s, thanks to significant improve-
ments in public health, and later on the arrival
of antibiotics (Persson 2010). However, TB
still remains a major global health problem,
ranking as the second leading cause of death
from an infectious disease worldwide, after the
human immunodeficiency virus (HIV) (World
Health Organization (WHO) 2012a). More-
over, the rise of multi-drug-resistant (MDR
TB) and extensively drug-resistant (XDR TB)
strains of TB in the 1980s, along with the
overlap of TB with HIV infections, led the
WHO to declare TB as a global public health
emergency in 1993. Despite continuing prog-
ress since, including a move to global targets
for the reduction in TB cases and deaths, about
9 million new TB cases are detected and 1.5
million people still die from TB every year
(WHO 2012a). The prevalence of the disease
is also very skewed towards poor developing
countries, with 60 per cent of cases in the
South-East Asia and Western Pacific regions
alone, and another 25 per cent of cases in
Africa (WHO 2012a).
Being an airborne communicable disease,
TB poses a major threat not only to countries
with a high burden of TB but also to the entire
world due to the increase in travel and migra-
tion. For example, the high prevalence of TB in
northern Europe in the eighteenth and
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nineteenth centuries caused a disease transmis-
sion, due to the effects of migration, to highly
susceptible populations in Africa, Asia and the
Americas, resulting in epidemics in those popu-
lations (Davies 1995). Over the last 50 years,
this direction has flipped. The incidence of TB
has fallen dramatically in developed countries
while it remains high in developing countries,
with immigration now more likely from devel-
oping to developed countries as global mobility
rises.As a result, most of new active TB cases in
developed countries occur among foreign-born
migrants and travellers to areas with a high TB
burden (Gaudette & Ellis 1993; McKenna et al.
1995; Cobelens et al. 2001).
Existing literature tells us that investing in
the control of TB overseas brings significant
domestic returns (Schwartzman et al. 2005).
Yet most of the resources provided for the fight
against TB come from poor developing coun-
tries (WHO 2012a). Developed countries typi-
cally prevent TB by implementing TB
screening programs for immigrants overseas,
or at ports of entry, or after arrival (Horsfield &
Ormerod 1986; Bonvin & Zellweger 1992;
Thomas & Gushulak 1995; Binkin et al. 1996;
Alvarez et al. 2011). Nevertheless, no matter
how aggressive those screening programs can
be, the inherent attributes of TB, especially
latent TB which is not easy to detect, prove
that sustainable and extensive health outcomes
are not likely to be achieved unless the epi-
demic is tackled at its root.
In this article, we focus on the case for Aus-
tralia investing in the control of TB in its
closest neighbour, Papua New Guinea (PNG).
This case is particularly interesting due to
extensive population mobility and the large
gap in living standards, health services and
especially TB prevalence between the two
countries. Of major importance is the increas-
ing concern in Australia over the potential and
ongoing importation of MDR TB from PNG,
and a possible outbreak of MDR TB in the near
future due (partly) to the frequency of MDR
TB observed among PNG patients seeking
health care services in Australia (Lumb et al.
2007; Gilpin et al. 2008).
In part, to protect its population, but also for
development assistance in terms of improving
health outcomes for people in PNG, Australia
has implemented some safeguard measures. At
its beginning, a few TB clinics were opera-
tional, for years, in a treaty region (i.e., islands
between PNG and Australia which allow for
free movement of traditional inhabitants) to
provide diagnosis and treatment of TB
patients. These were controversially closed in
early 2010, mostly on the grounds of funding
shortfalls. Facing domestic pressure after the
closure of these TB clinics, the Government of
Australia announced a more ‘long-term’ and
comprehensive strategy to strengthen the
capacity to cope with TB in Western Province
in PNG, which lies across a relatively small
stretch of sea from Australia. In particular,
Australia’s Aid Program has committed to a
10-year strategy ‘to ensure effective and sus-
tained TB services’ (AusAid 2012). An initial
US$ 11.4 million in 2012 prices1 over 4 years
starting from 2012, in particular, was provided
by Australia’s Aid Program to strengthen TB
control in the Torres Strait Islands (TSI).
This article examines whether we have the
right framework for making a proper policy
choice in Australia’s support of the control of
TB in PNG. In particular, we ask the following:
(i) What would be the returns to Australia in
investing in TB control in PNG? (ii) How long
and how extensive should the TB program be in
order to be the most cost-effective forAustralia,
both from its own point of view as well as from
an Official Development Assistance (ODA)
perspective? To answer these questions, we first
summarise the results from a TB spread model
between South Fly, the southern most district of
Western Province, and the TSI. We then present
results from the overlay of two economic
decision-making approaches, including cost
utility analysis (CUA) and cost-benefit analysis
(CBA) on the TB spread model. Finally, we
briefly discuss the limitations and remaining
uncertainties in our analysis that need to be
taken into account in the decision-making
process.
1. This is equivalent to AU$ 11 million using the average
of monthly exchange rates of AUD to USD for the year
2012 provided by the Reserve Bank of Australia (Reserve
Bank of Australia 2014).
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2. Background
PNG is a resource-rich and largely agricultural
economy. The vast majority of Papua New
Guineans make their income from self-
employment as farmers in the informal sector.
One third of the population is poor and almost
90 per cent of the population lives in rural areas
(Foster et al. 2009). Since nearly 50 per cent of
the total land is mountainous, widely scattered
rural communities are often inaccessible. Fur-
thermore, as one of the most culturally diverse
countries in the world, PNG has more than 800
distinct languages, spoken by numerous clans.
This cultural diversity, coupled with strong
allegiance to clan groups rather than to the
country as the whole, along with poor infra-
structure, makes it hard to achieve nationwide
development goals and often hampers the
quality of basic services at the point of delivery.
PNG is one of the countries with a very high
burden of TB in the Western Pacific region. In
2009, it had an estimated (and likely underesti-
mated) TB prevalence rate of 337 per 100,000,
a TB death rate of 26 per 100,000, and a total of
12,306 new TB cases (all forms) (WHO 2011;
McBryde 2012). The directly observed therapy,
short-course (DOTS)2 program has been imple-
mented slowly since its inception in 1997, with
a coverage of only 14 per cent as of 2007 (WHO
2009b). Due to weak health care services and a
lack of supporting resources, the successful
treatment rate is only 58 per cent (WHO 2013),
much lower than the global target of 85 per cent
(WHO 2009b). This, coupled with a high
default rate in treatment, likely contributes to
the apparently high rate of MDR TB in PNG
(WHO 2011).
The control of TB in PNG is of special inter-
est to Australia. Being less than 5 km away, at
some points, PNG is its closest neighbour. Fur-
thermore, Australia’s TSI, which straddles the
border between the two countries, is under a
treaty signed between the two countries that
allows for the relatively free movement for
people of both countries in the region. As Aus-
tralia has very low incidence of TB and one of
the most well-resourced health care systems in
the world, there has been an observed and sig-
nificant number of cross-border health care
requests by PNG nationals. High rates of MDR
TB notifications among PNG patients seeking
health care in Australia have also, as indicated
above, raised serious concerns over a possible
and ongoing transmission of MDR TB from
PNG, and a possible MDR TB outbreak in
Australia in the near future (Lumb et al. 2007;
Gilpin et al. 2008). These concerns form the
backdrop of Australia’s support to TB-related
programs in PNG.
In part, to cope with this unwanted event,
Australia provides about 12 per cent of its
annual aid budget to PNG, with one fifth going
to the health sector (Foster et al. 2009), and a
10-year strategy to strengthen the capacity to
cope with TB in Western Province, which
borders with Australia, was launched in 2012.
For the first four years, an initial US$ 11.4
million was provided to finance a TB isolation
ward and enhance capacity for MDR TB diag-
nosis and treatment in Daru, to supply MDR
TB patients with second-line drugs for 1 year
of the required 18-month treatment, along with
funding to World Vision to train and supervise
TB treatment and workers in South Fly, and for
the Western Province Department of Health to
conduct regular outreach clinics by boat
(AusAid 2012).
3. Theoretical Framework for Economic
Evaluation in the Health Sector
CBA is the principal tool for making practical
choices in economics. CBA’s main criterion is
to adopt projects with positive net present
values (NPV), or to rank projects by their NPV
with future costs and benefits discounted at the
social discount rate. In basic terms, NPV is the
difference between the present value of all
benefits and costs. The challenge to the
2. Being developed and promoted by WHO, DOTS has
been widely endorsed by national TB programs. This is the
basic package that underpins the WHO-initiated Stop TB
Strategy. DOTS has five components, namely (i) political
commitment, (ii) diagnosis using sputum smear micros-
copy, (iii) a regular supply of first-line anti-TB drugs, (iv)
a standardised treatment regimen of 6–8 months directly
observed by a health worker, and (v) a standard system for
recording and reporting the number of cases detected by
national TB control program (WHO 2012a).
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application of CBA in the health sector is in
‘monetising’ the benefits and consequences of
health interventions. This challenge is not only
technical, as values here are hard to measure,
but raises significant ethical issues as well,
since quantifying human health and life in
terms of money is not always appealing to
policy-makers and the public.
To address the ethical concerns in putting
money values on health benefits, CUA has
been developed to aid decision-making in the
health sector. CUA differs from CBA in the
sense that CUA measures health improve-
ments due to an intervention by a combination
of a quality of life measure and life-years
saved. To this end, the incremental costs of a
program, within this particular point of view,
are compared with the incremental health ben-
efits of the program (Drummond et al. 2005).
Projects are then selected to maximise health
benefits given a budget constraint.
Two commonly used metrics in measuring
health consequences in CUA are quality-
adjusted life-years (QALY) and disability-
adjusted life-years (DALY). First used in
1976, QALY for a single year of an individu-
al’s life is a product of 1 year and a health-
related quality of a life weight attached to that
year of life (Zeckhauser & Shepard 1976).
This weight is bounded by [0,1] where 1 rep-
resents a year lived with full health and 0
means death. As a variant of QALY, DALY
was developed as a measurement unit to quan-
tify the global burden of disease and injury on
human populations (Murray & Lopez 1996).
DALY has been recommended by WHO for
use in generalised cost-effectiveness analysis,
which aims to evaluate a wide range of pos-
sible health interventions to identify the
optimal package of health care services deliv-
ered within a fixed budget (Edejer et al. 2003).
While conceptually similar, DALY differs
from QALY in a number of aspects. The most
notable difference is the disability weight. In
QALY, the weight is developed from prefer-
ences, either those of the general public or
those of patients. In DALY, on the other hand,
the weight measures social (not individual)
preferences, based on person tradeoff scores
from a panel of health care workers who met in
Geneva in August 1995. Furthermore, DALY
has only seven discrete health values on health
states, in addition to death (being 1) and fully
healthy (being 0), in contrast to the life quality
weight in QALY which is continuous in the
range [0,1]. Finally, DALY also gives lower
weight to the young and the elderly. (For a
detailed discussion on the difference between
QALY and DALY, please refer to Drummond
et al. 2005 and Sassi 2006.)
Despite the usefulness of CUA in health
sector, CBA is still necessary in many cases
since it allows for direct comparisons of cost-
effectiveness and economy-wide measures of
allocative efficiency. In CBA, health outcomes
need to be quantified in money. There are three
general approaches in doing so: (i) human
capital measures, (ii) revealed preference for a
health outcome and (iii) stated preferences or
‘willingness-to-pay’(WTP) for a health service
or outcome. Given problems with often imper-
fect labour markets in the human capital
approach and the context and job specificity
needed for revealed preference approaches,
WTP appears the most promising in its attempt
to measure underlying consumer demand for
non-market values and products, such as health
care interventions (Drummond et al. 2005).
Admittedly, there are some concerns about
equity in using WTP, as WTP takes as given the
underlying income distribution in the popula-
tion. However, these concerns should not be an
issue in this study as we take the perspective of
two countries, namely Australia and PNG,
separately in allocating resources to PNG.
4. Costs and Benefits of TB Control
for Policy-Making
In this section, we first summarise results from
a TB spread model between TSI and South Fly.
We then present results from CUA and CBA
with a particular focus on (i) what would be the
returns to Australia in investing in TB control
in PNG, and (ii) how long and how extensive a
TB control program should be in order to be
the most cost-effective for Australia.
The TB control program in PNG that we
consider is an expansion of basic DOTS in
South Fly. Basic DOTS, which covers only
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infectious (pulmonary) TB cases, is highly rec-
ommended in resource-poor countries (WHO
2006b). In PNG, the current level of DOTS
coverage is 14 per cent (WHO 2009a). Despite
being low, this DOTS coverage level is still
likely to be an overestimate for the small, iso-
lated communities of the South Fly district
(McBryde 2012). Furthermore, the weak TB
control program in PNG, which results in low
success treatment and high default rates,
coupled with poor clinical practices due to an
inadequate health system, limited diagnostic
capacity and the lack of availability of drug
resistance testing facilities, adds considerable
risks to implementing a more sophisticated
treatment program, and especially for MDR
TB in PNG (WHO 2010b; Lokuge et al. 2012).
WHO, in particular, gives specific guidance on
rolling out MDR TB treatment as follows: ‘In
principle, MDR treatment should be intro-
duced only in well-performing DOTS pro-
grammes. Before focusing on curing MDR-TB
cases, it is critical to “turn off the tap”, i.e., to
strengthen poor programmes so that they stop
giving rise to MDR-TB’ (WHO 2010b, p. 18).
Therefore, expanding basic DOTS is clearly a
top priority and the most reasonable starting
point in PNG for the time being.
We consider various levels of basic DOTS
coverage expansion as well as various lengths
of TB control programs. Expansion levels
include 30 per cent, 50 per cent, 65 per cent,
80 per cent and 95 per cent basic DOTS cov-
erage. We assume a lag of 4 years for PNG to
reach the 95 per cent coverage level. The time
required for fully achieving other expansion
levels is somewhere between 0 and 4 years,
depending on how extensive the expansion is.
In terms of TB program length, it can be as
short as 4 years, being in line with the initial
funding provided by Australia’s Aid Program,
or as long as 10 years, 20 years and 30 years.
4.1 Epidemiological Model: Brief
Description and Results
We use a metapopulation modelling technique
to model the connection in TB prevalence
between TSI and South Fly (Hanski & Gilpin
1997; Hanski & Gaggiotti 2004; Keeling &
Rohani 2008). The results are based on the
model described in Hickson et al. (2012),
which is a combination of metapopulation and
compartment modelling techniques. The
metapopulation technique allows for regions
with different attributes, or in this case various
burdens of TB, their transmission and access to
treatment. This feature of the metapopulation
technique is of special importance to our
analysis given the large differences between
TSI and South Fly in these attributes. Our
model has four subpopulations: (i) Papua New
Guineans in South Fly, (ii) Papua New Guin-
eans in TSI, (iii) Australians in TSI, and (iv)
Australians in South Fly, in order to track
population dynamics in South Fly and TSI, as
well as the travel between the two regions.3
For each subpopulation, each stage of the
disease and treatment is encapsulated in six
compartments: those susceptible, latently
infected, clinically active with only non-
pulmonary TB, clinically active with at least
pulmonary TB, detected and treated for the
first time, and being retreated. The resulting
model, combining the metapopulations with
the compartments, is in the form of a set of
non-linear ordinary differential equations
solved using Matlab version R2012b. See
Nguyen et al. (2013) for details on equations.
The model was calibrated based on histori-
cal patterns and the current situation in PNG
and TSI. Some parameter values used in the
model were taken from the literature, and
some assumptions were made based on what
data were available, and in order to simplify
the model as much as possible. Details on
model calibration, assumptions, parameters
and their values are in Hickson et al. (2012). A
sensitivity analysis of this model was con-
ducted in Hickson et al. (2011), where it was
found that the parameter that most influenced
the cumulative number of TB cases was the
rate that latently infected patients become
clinically active in PNG.
3. The rates of departure and return of Australian and
Papua New Guinean nationals to simulate travel between
South Fly and TSI were estimated based on data from
Department of Immigration and Citizenship (2010).
Please see Hickson et al. (2012) or Nguyen et al. (2013)
for details.
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There are two reasons why we only focus on
South Fly and TSI as the representative regions
for PNG and Australia, respectively, in our
model. First, regions in each country are
heterogenous, with South Fly and TSI being
among the most disadvantaged in their respec-
tive countries. Second, and more importantly,
the frequent and relatively unscreened move-
ments between the countries occur mostly
between these two communities due to an
existing treaty, so that the concerns about TB
spread from PNG to Australia centre around
this border area.
Given the links between South Fly and TSI
in terms of TB incidence and prevalence,
expanding basic DOTS coverage in South Fly
also delivers direct benefits to TSI. For
example, a fall of 12 per cent in TB prevalence
in TSI would be achieved if basic DOTS cov-
erage in South Fly was expanded to 95 per cent
for 20 years (detailed results are in Nguyen
et al. 2013). With this intervention, the results
would be even more impressive in South Fly,
with TB prevalence being more than halved.
These results deserve special consideration
given that half of the patients recently detected
with MDR TB in Australia came from this
cross-border region (Lumb et al. 2007).
4.2 Economic Evaluation
As discussed in Section 3, the cost of an inter-
vention (i.e., expanding the basic DOTS cov-
erage) is the same in CUA and CBA. It
includes expenses to cover diagnosis (with
sputum smear microscopy and X-rays), health
care centre visits, drug supplies for a 6-month
treatment course for first-time treated TB
patients and an 8-month treatment course for
retreated TB patients, as well as program man-
agement. Treatment regimens follow WHO’s
guidelines (WHO 2010b) and drug prices were
drawn from Global Drug Facility (2012).
Assumptions on the number of health care
visits were based on Baltussen et al. (2005).
Detailed costs per TB patient are provided in
the Appendix 1.
In order to calculate the benefit for CUA, we
need not only the distributions of
subpopulations in terms of their health states
captured in compartments of the epidemiologi-
cal model, but also their age, gender and life
expectancy. Incorporating those details into the
model is computationally complicated. There-
fore, we kept each subpopulation classified by
six health states as described in Section 4.1
intact, with only natural birth rates, natural
death rates and the death rates induced by TB
related health states being taken into account.
Information on age and gender was incorpo-
rated into the model results for economic evalu-
ation after the model was solved. Age and
gender distributions in TSI are from population
projections by Australian Bureau of Statistics
(2008), while those for South Fly were obtained
from projections by the United Nations (2010).
Life expectancy of Australian nationals was
taken from the life table 2008–2010 estimated
by Australian Bureau of Statistics (2011), while
that of Papua New Guinean nationals was
drawn from the life table 2011 estimated by
WHO (2012b). Finally, the health-related
quality of life weight for TB patients used in our
article was provided by Tengs and Wallace
(2000) while the disability weight was drawn
from Murray and Lopez (1994). The numbers
of QALY and DALY for each subpopulation in
the status quo, and when basic DOTS is
expanded, were then calculated using informa-
tion on health states, age, gender, life expec-
tancy, quality of life and disability weights.
The benefit for CBA was obtained by con-
verting QALY into money using WTP. For
TSI, we used a WTP per QALY of US$ 58,766
(in 2012 prices) estimated by Shiroiwa et al.
(2010). Since estimates for WTP per QALY
are available for only a handful countries in the
world, we do not have that information for
PNG. Instead, we used gross domestic product
(GDP) per capita in PNG of US$ 2,184 for the
year 2012 (World Bank, 2014) as a proxy for
WTP per QALY in PNG. As discussed in
Section 3, using different WTP per QALY
could raise concerns about equity since it is
always preferred to allocate resources to save
QALY in areas where QALY is more valued,
namely Australia in this case. Fortunately, this
is not a concern for us since we do not consider
a joint investment decision for Australia and
PNG.
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The health benefit from expanding basic
DOTS coverage from 14 per cent to any level
of interest, at any point in time, is the accu-
mulated difference between the health out-
comes, be it in money, DALY or QALY, with
the expansion in place and those under the
current 14 per cent basic DOTS coverage.
Likewise, the corresponding health cost is the
cost of expanding the basic DOTS coverage
level from the current 14 per cent to the desir-
able level of expansion. All costs and benefits
in our article were discounted at 3 per cent as
recommended for the health sector
(Weinstein et al. 1996; Edejer et al. 2003).
Unless specified, all values in money are in
USD in 2012.
Table 1 presents costs per DALY, QALY
and NPVs for Australia and PNG. It is impor-
tant to note that since there is a spillover effect
of expanding basic DOTS in South Fly on TSI
(Section 4.1), the cost borne by Australia is the
combined cost incurred in TSI and in South
Fly. For PNG, only the cost incurred in PNG is
taken into account. Columns 3 and 7 of
Table 1, respectively, present the costs of
expanding basic DOTS in South Fly from the
Australian and PNG perspectives. While the
two costs look virtually the same, there is some
deduction in the cost of detecting and treating
TB patients in TSI, thanks to basic DOTS
expansion in South Fly. The benefit for Aus-
tralia and PNG, on the other hand, are the
accrued benefits to Australian and Papua New
Guinean nationals, respectively.
CUA
Costs per DALY and costs per QALY for TSI
are presented in columns 5 and 6 while those
for South Fly are presented in columns 9 and
10 of Table 1. A similar pattern is revealed for
the two regions: the longer the TB program is,
the cheaper it is to avert a DALY or to save a
QALY. However, it is much more expensive to
save a QALY or to avert a DALY in TSI than in
Table 1 Cost per DALY, QALY and NPV (US$ 2012) of Expanding Basic DOTS Coverage in South Fly from the
Current Level of 14 Per Cent in South Fly
TB programs TSI South Fly
Years
Basic
DOTS
coverage
(%)
Total
discounted
cost (million)
NPV
(million)
Cost per
DALY
(thousand)
Cost per
QALY
(thousand)
Total
discounted
cost (million)
NPV
(million)
Cost per
DALY
Cost per
QALY
4 30 1.4 0.34 75 47 1.4 269 18 11
50 3.0 0.33 84 53 3.0 518 20 13
65 4.6 −0.60 107 68 4.6 645 26 15
80 5.8 −1.08 114 72 5.8 746 28 17
95 6.4 −1.15 113 72 6.4 828 28 17
10 30 3.1 9.8 22 14 3.1 1,170 9.2 5.8
50 6.4 17 24 16 6.4 2,120 11 6.6
65 9.8 19 31 20 9.8 2,580 13 8.2
80 12 21 33 22 12 2,920 14 9.0
95 13 22 33 22 13 3,180 14 9.0
20 30 5.8 42 10 7.2 5.8 3,080 6.3 4.1
50 12 73 12 8.1 12 5,410 7.2 4.7
65 18 83 15 10 18 6,480 9.0 5.9
80 22 92 16 11 22 7,250 9.8 6.5
95 23 100 16 11 23 7,830 9.9 6.5
30 30 8.5 93 6.7 4.9 8.5 5,410 4.9 3.4
50 17 160 7.5 5.5 17 9,340 5.6 3.9
65 25 185 9.5 7.0 25 11,100 7.1 4.9
80 30 204 10 7.6 30 12,400 7.7 5.3
95 33 220 10 7.6 33 13,300 7.7 5.3
DALY, disability-adjusted life-years; NPV, net present values; QALY, quality-adjusted life-years; TB, tuberculosis; TSI,
Torres Strait Islands.
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South Fly. For example, it would cost US$
84,000 to avert a DALY in TSI in comparison
with only US$ 20 in South Fly. Furthermore,
the length of a TB program has a more sub-
stantial impact on the cost per DALY and the
cost per QALY in TSI than in South Fly. For
example, the cost to avert a DALY in a 30-year
TB program is only less than a tenth of that in
a 4-year TB program in TSI, while the corre-
sponding comparison is a fourth in South Fly.
There are a couple of factors to consider in
these results. First, it takes time for the benefit
to be materialised while the cost is required
upfront. TB patients need to be treated for 6–8
months. To this end, an intervention needs to
be in place for a good while before it has an
impact on TB prevalence and TB incidence to
generate health benefits. Second, basic DOTS
coverage is very low in South Fly, resulting in
large health benefits being generated quickly
during an intervention. For TSI, on the other
hand, the spillover effects from a basic DOTS
expansion in South Fly take a much longer
time to be effective. It, thus, takes less time for
the benefit to ‘catch up’ with the cost in South
Fly compared with TSI.
Against the decreasing trend over time of
costs per DALY and QALY, the questions to be
asked are whether basic DOTS expansion in
South Fly is cost-effective for Australia and
over what time period? Looking solely from an
Australian perspective, we only count the ben-
efits accrued to Australians while Australia
pays for the cost of basic DOTS expansions in
South Fly. Using the cost per DALY, a health
intervention is considered to be cost-effective
for a country when the cost per DALY of the
intervention is equal to its GDP per capita
(Sachs 2001; Evans et al. 2005). Of course, the
lower the cost per DALY is relative to its GDP
per capita, the more cost-effective the inter-
vention would be for the country. We use Aus-
tralia’s GDP per capita of US$ 67,442 in 2012
(World Bank, 2014) as the key benchmark.
Basic DOTS expansion in South Fly would
thus be cost-effective, extrapolating from
Table 1 (column 5), if Australia maintains its
support for at least 5–6 years, depending on
the coverage level, or beyond (detailed results
are available upon request). Using the cost per
QALY, on the other hand, a health intervention
is considered to be cost-effective for a country
when the cost per QALY of an intervention is
less than or equal to its people’s WTP per
QALY. The WTP per QALY for Australians is
estimated to be US$ 58,766 (Shiroiwa et al.
2010). Comparing the cost per QALY (column
6 of Table 1) with WTP per QALY yields
results that corroborate the ones using the cost
per DALY.
From an ODA prospective, is TB control in
South Fly a good investment for Australia?
Yes, indeed, since the cost per DALY in
incredibly low, ranging from US$ 5 to US$ 28
(column 9 of Table 1), in South Fly, thanks to
large gains of basic DOTS program expansion
from its existing low coverage level combined
with a prior burden of TB that is high. For this
reason, basic DOTS coverage expansion in
South Fly is positioned well in the range of the
top 10 best ‘health buys’ in developing coun-
tries (Measham et al. 2006).
Finally, should PNG itself invest in TB
control in South Fly? Both cost per DALY
and QALY suggest that this investment is
very cost-effective for PNG as well.
However, an open question remains as to
whether this relatively poor country can
afford this investment?
CBA
Having the same cost as in CUA, CBA has its
benefit obtained by converting QALY into
money using WTP. NPVs for TSI are pre-
sented in column 4 while NPVs for South Fly
are in column 8 of Table 1. For programs that
run beyond 4 years, NPVs for TSI and South
Fly exhibit the same pattern: the longer the
TB program or the more extensive the basic
DOTS expansion is, the higher is the
NPV. This pattern is also revealed in
Figures 1 and 2.
One distinctive feature for TSI is that the
more extensive the basic DOTS expansion in
South Fly is, the larger the losses that would
occur if Australia stops funding the expansion
after 4 years (Table 1, column 4). This result
stems from the high start-up costs and likely
delay to get required facilities and human
resources ready to widely expand basic DOTS
Nguyen et al.: Aid and the Control of Tuberculosis 371
© 2014 The Authors. Asia and the Pacific Policy Studies
published by Wiley Publishing Asia Pty Ltd and Crawford School of Public Policy at The Australian National University
coverage. This high start-up cost only pays off
in the long run. Indeed, only from the sixth
year of the program does the NPV generated
from the 95 per cent basic DOTS coverage
dominate the NPVs generated by all other
lower levels of coverage (Figure 1, left panel).
Suppose, for example, Australia continues to
support the expansion for 10 years, as prom-
ised, it would cost Australia about US$ 13
million in total or US$ 1.3 million per year to
expand basic DOTS coverage to 95 per cent in
South Fly. In return, the NPV generated would
be about US$ 22 million. On the other hand,
for the same program length, the cost would be
halved for a 50 per cent basic DOTS expan-
sion, but the corresponding NPV would be
only US$ 17 million.
Two questions are motivated by Austra-
lia’s recent 10-year commitment to assist
with TB control in Western Province, where
South Fly is located, with an initial funding
of US$ 11.4 million for the first 4 years.
First, is a 10-year commitment optimal? The
answer is likely negative. Stopping the
support after 10 years would be unwise since
major added benefits from the intervention
will only be generated, in a clear exponential
manner, beyond 10 years, producing substan-
tive net gains (Figure 1, right panel). For
example, if Australia funded the basic DOTS
expansion to 95 per cent for 20 instead of 10
years, the cost of the support would be almost
doubled, increasing from about US$ 13
million to US$ 23 million. However, the NPV
from a 20-year program is roughly US$ 100
million, almost four times higher than the
NPV of US$ 22 million from a 10-year
program (Table 1, column 4). Indeed, Austra-
lia would probably be better off committing
to the program in perpetuity since the
program cost keeps falling while the program
benefit keeps increasing beyond the program
break-even point of year 5–6. Although the
exact timing of the break-even point is sensi-
tive to the assumption of a 4-year lag for
PNG to reach the 95 per cent coverage level
Figure 1 NPV of Expanding Basic DOTS Coverage in South Fly from the Current Level of 14 Per Cent for Aus-
tralia (Left Panel for Years 0–10; Right Panel for Years 0–30)
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discussed earlier, the main results that are in
favour of the program being place in perpe-
tuity remain.
The second question is whether the initial
US$ 11.4 million for the first 4 years would be
enough to control TB in Western Province?
The cost for expanding basic DOTS coverage
in South Fly to 95 per cent for 4 years is US$
6.4 million. Suppose the cost of expanding
basic DOTS in other parts in Western Province
is similar to that in South Fly, as are the param-
eters required for the epidemiological model,
then the required cost for expanding the basic
DOTS in Western Province is about US$ 19.2
million. That is, the cost is in proportion to
population size, with the total population of
Western Province being three times as much as
that in South Fly. As a result, if Australia wants
to expand basic DOTS in Western Province to
95 per cent coverage for 4 years, it needs to
increase its current funding commitment by
about US$ 7.8 million (or AU$ 7.25 million).
It is also worth noting that our required
funding estimate is only for treating TB drug-
sensitive (pulmonary) patients, not for any of
MDR TB cases that Australia would also like
to target.
From PNG’s perspective, it is also clear
from Figure 2, as well as Table 1 (column 8),
that the longer and the more extensive the
basic DOTS expansion is, the higher are the
NPVs that are generated. The same open ques-
tion as above remains.
5. Conclusion
Our study has attempted to analyse the case
for the assistance provided by Australia for
the control of TB in PNG. By overlaying two
economic decision-making approaches, CUA
and CBA, on a TB spread model between the
two neighbouring regions of these two coun-
tries, it is able to shed light on the likely costs
and benefits of this investment. The results
show that this assistance is clearly effective in
controlling TB, and thus achieving one of the
Figure 2 NPV of Expanding Basic DOTS Coverage in South Fly from the Current Level of 14 Per Cent for PNG
(Left Panel for Years 0–10; Right Panel for Years 0–30)
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Millennium Development Goals, since the
cost per DALY averted in PNG is positioned
well in the range of the top 10 best health
buys in developing countries, regardless of
the length of the program. Further, the longer
the assistance is, the more effective it would
be. The findings also indicate that Australia
can only benefit from this investment if it
continues the support the program for at
least 6 years. In fact, it would be optimal
for Australia to provide this support in
perpetuity.
With these results in mind, there are at
least three issues worth exploring in the
decision-making process. First, it would be
useful to further investigate the local esti-
mates for parameters used in our costing, and
to some extent the TB spread model. The cost
of running an effective TB program and
extending its coverage in South Fly, in par-
ticular, is likely to be large given the weak
state of health services and the health system
there. Little information other than available
estimates from other similar developing coun-
tries is available for us to take this issue into
account. Second, there is a need to investigate
collaborative opportunities in controlling
other infectious diseases, such as HIV and
malaria, to enhance allocative efficiency and
avoid the otherwise inevitable crowding-out
of resources allocated to those diseases.
Finally, patients’ attitudes, culture and local
practices need to be further investigated as
they are found to have a profound effect on
the success of TB programs (Thiam et al.
2007).
May 2014.
Appendix 1: Cost Per TB Patient under Different Basic DOTS Coverage in PNG,
US$ 2012
Coverage Cost item Q’ty
South Fly TSI
Unit cost T1 T2 Unit cost T1 T2
14% Program management and supervisiona 57 57 711 711
Diagnosis
Smear testb 30 4.1 122 122 21.6 649 649
X-rayc 9 10.1 91 91 48.4 435 435
Monitoring diagnosis
Smear testb 6 4.1 24.5 24.5 21.6 130 130
Drugsd 43.7 177 43.7 177
Health centre visitse 43 10.3 441 28 1,206
Health centre visitse 59 10.3 605 28 1,654
Total cost per patient 779 1,076 3,174 3,756
30% Program management and supervisiona 221 221 711 711
Diagnosis
Smear testb 30 4.1 122 122 21.6 649 649
X-rayc 9 10.1 91 91 48.4 435 435
Monitoring diagnosis
Smear testb 6 4.1 24.5 24.5 21.6 130 130
Drugsd 44 177 43.7 177
Health centre visitse 43 10.3 441 28 1,206
Health centre visitse 59 10.3 605 28 1,654
Total cost per patient 944 1,241 3,174 3,756
50% Program management and supervisiona 402 402 711 711
Diagnosis
Smear testb 30 4.1 122 122 21.6 649 649
X-rayc 9 10.1 91 91 48.4 435 435
Monitoring diagnosis
Smear testb 6 4.1 24.5 24.5 21.6 130 130
Drugsd 44 177 43.7 177
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Coverage Cost item Q’ty
South Fly TSI
Unit cost T1 T2 Unit cost T1 T2
Health centre visitse 43 10.3 441 28 1,206
Health centre visitse 59 10.3 605 28 1,654
Total cost per patient 1,124 1,421 3,174 3,756
65% Program management and supervisiona 665 665 711 711
Diagnosis
Smear testb 30 4.1 122 122 21.6 649 649
X-rayc 9 10.1 91 91 48.4 435 435
Monitoring diagnosis
Smear testb 6 4.1 24.5 24.5 21.6 130 130
Drugsd 44 177 44 177
Health centre visitse 43 10.3 441 28 1,206
Health centre visitse 59 10.3 605 28 1,654
Total cost per patient 1,387 1,684 3,174 3,756
80% Program management and supervisiona 810 810 711 711
Diagnosis
Smear testb 30 4.1 122 122 21.6 649 649
X-rayc 9 10.1 91 91 48 435 435
Monitoring diagnosis
Smear testb 6 4.1 24.5 24.5 21.6 130 130
Drugsd 44 177 44 177
Health centre visitse 43 10.3 441 28 1,206
Health centre visitse 59 10.3 605 28 1,654
Total cost per patient 1,533 1,830 3,174 3,756
95% Program management and supervisiona 839 839 711 711
Diagnosis
Smear testb 30 4.1 122 122 21.6 649 649
X-rayc 9 10.1 91 91 48 435 435
Monitoring diagnosis
Smear testb 6 4.1 24.5 24.5 21.6 130 130
Drugsd 44 177 44 177
Health centre visitse 43 10.6 454 28 1,206
Health centre visitse 59 10.6 624 28 1,654
Total cost per patient 1,575 1,878 3,174 3,756
Notes: T1: infectious TB patient treated for the first time; T2: infectious TB patient retreated. Costs only occur
in these two compartments. The consumer price indices (CPI) for Australia and PNG are obtained from World
Bank (2014) while exchange rates are from the Reserve Bank of Australia (2014).
(a) Costs for program management and supervision per patient are from Baltussen et al. (2005), where
details of the approach for estimating those costs are discussed in Evans et al. (2005). We use data for
Sear-D (Bangladesh, Bhutan, Democratic People Republic of Korea, India, Maldives, Myanmar, Nepal,
Timor Leste) as data are not available for Australia or PNG or for anywhere else in the Pacific region. As
data are available for only DOTS coverage levels of 50 per cent, 80 per cent and 95 per cent in Sear-D, we
use an extrapolation method to estimate the program management and supervision cost for other DOTS
coverage levels.
(b) and (c) Diagnosis is based on an assumption that one per 10 TB suspects presenting to the health centre
is tested smear-positive (WHO 2010a; Baltussen et al. 2005). Since each suspect is tested with three smear
tests, this means that 30 smears are used to detect one smear-positive case. The remaining nine remain
suspected case and are tested with an X-ray. This means for every case that is tested smear-positive, nine
X-rays are performed which will detect the x number of smear-negative cases. The number of X-rays used for
case detection of x smear-negative cases is then equal to 9*smear-positive cases detected (and is independent
of x). Monitoring diagnosis is based on (Baltussen et al. 2005). Unit costs for smear tests and X-rays are from
(WHO 2006a, table 2, p. 58), where prices for PNG and Australia are, as a proxy, given by the average prices
for Indonesia and America for 2001–2003 and 2001–2002, respectively, which in turn are inflated by the CPI
indices of PNG and Australia to obtain 2012 prices.
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(d) The regiment for T1 is based on the recommendation 1.1 in (WHO 2010b, p. 32): 6-month treatment with
2-month intensive and 4-month continuation phases. As we do not take into account multi-drug resistance
tuberculosis and the drug susceptibility testing equipment is not available in PNG (Lumb et al. 2008), we use
recommendation 7.3.2 (WHO 2010b, p. 40) for T2: 8-month treatment of first-line drugs. Drug costs are
based on Global Drug Facility (2012) first-line drug calculation sheet, version 13/7/2011, which uses the
lowest possible price per product the Global Drug Facility is able to provide under the current agreement with
its suppliers, accounting for freight, insurance and other fees. Quantities of drugs per patient are calculated
based on the average weight band of 40–54 kg.
(e) We use assumptions from Baltussen et al. (2005) on the frequency of health centre visits as there is no
clear standard by WHO. The cost per health centre visit is from WHO estimates of unit costs for patient
services for 14 Global Burden of Disease Regions (WHO, 2014).
The opinions expressed in the Policy Forum are those of the author(s) alone and do not necessarily reflect
those of the Journal’s Editors and partners.
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